A股異動 | 新天藥業漲停 參股公司子公司獲藥品註冊批件
格隆匯3月16日丨新天藥業(002873.SZ)漲停,報20.33元,暫成交1670萬元,最新總市值23.8億。公司昨日公告稱,參股公司匯倫生物的全資子公司匯倫江蘇藥業近日收到國家藥品監督管理局核准簽發的《藥品註冊批件》,藥品名稱為注射用西維來司他鈉,是國內獲批的唯一用於治療伴有全身性炎症反應綜合徵的急性肺損傷(ALI)和急性呼吸窘迫綜合徵(ARDS)藥物。ARDS是呼吸系統的急危重症,非典型的嚴重急性呼吸綜合徵(SARS)、中東呼吸窘迫綜合徵(MERS)及流感病毒引起的肺炎皆可導致ARDS。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.